JP2023514568A - ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ - Google Patents

ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ Download PDF

Info

Publication number
JP2023514568A
JP2023514568A JP2022548896A JP2022548896A JP2023514568A JP 2023514568 A JP2023514568 A JP 2023514568A JP 2022548896 A JP2022548896 A JP 2022548896A JP 2022548896 A JP2022548896 A JP 2022548896A JP 2023514568 A JP2023514568 A JP 2023514568A
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
usp1
parp
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514568A5 (https=
Inventor
アンドリュー アリステア ワイリー，
ソロモン マーティン シェンカー，
パメラ ジーン サリバン，
フランク ステグマイヤー，
アン ルイーズ カッゾー，
ハンラン リウ，
カースティン ウォルフ シンケビチウス，
Original Assignee
ケーエスキュー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケーエスキュー セラピューティクス， インコーポレイテッド filed Critical ケーエスキュー セラピューティクス， インコーポレイテッド
Publication of JP2023514568A publication Critical patent/JP2023514568A/ja
Publication of JP2023514568A5 publication Critical patent/JP2023514568A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022548896A 2020-02-14 2021-02-12 ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ Pending JP2023514568A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062976864P 2020-02-14 2020-02-14
US62/976,864 2020-02-14
US202063032245P 2020-05-29 2020-05-29
US63/032,245 2020-05-29
US202163146937P 2021-02-08 2021-02-08
US63/146,937 2021-02-08
PCT/US2021/017912 WO2021163530A1 (en) 2020-02-14 2021-02-12 Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors

Publications (2)

Publication Number Publication Date
JP2023514568A true JP2023514568A (ja) 2023-04-06
JP2023514568A5 JP2023514568A5 (https=) 2024-02-21

Family

ID=77291879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548896A Pending JP2023514568A (ja) 2020-02-14 2021-02-12 ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ

Country Status (11)

Country Link
US (1) US20230277533A1 (https=)
EP (1) EP4103165A4 (https=)
JP (1) JP2023514568A (https=)
KR (1) KR20220140732A (https=)
CN (1) CN115066235A (https=)
AU (1) AU2021218805A1 (https=)
CA (1) CA3168009A1 (https=)
IL (1) IL295149A (https=)
MX (1) MX2022009818A (https=)
TW (1) TW202140026A (https=)
WO (1) WO2021163530A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163530A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
US20240409538A1 (en) * 2021-10-19 2024-12-12 Impact Therapeutics (Shanghai), Inc. Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
IL312642A (en) * 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430049A4 (en) * 2021-11-12 2025-12-17 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
US20250161306A1 (en) * 2022-01-25 2025-05-22 KSQ Therapeutics, Inc. Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
JP2025531133A (ja) * 2022-09-20 2025-09-19 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体
CA3268518A1 (en) * 2022-09-23 2024-03-28 KSQ Therapeutics, Inc. THERAPEUTIC COMBINATIONS INCLUDING UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS (USP1) AND SELECTIVE PARP1 INHIBITORS
CN117384187B (zh) * 2022-09-30 2026-01-30 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
CN121866064A (zh) * 2023-06-16 2026-04-14 韩国科学技术研究院 包含BRCA特异性siRNA作为活性成分的用于预防或治疗靶向癌症的药物组合物
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025087460A1 (zh) * 2023-10-25 2025-05-01 海思科医药集团股份有限公司 一种吡啶并吡唑衍生物药物组合物及其应用
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑
WO2025153067A1 (zh) * 2024-01-19 2025-07-24 江苏亚虹医药科技股份有限公司 Usp1抑制剂及其医药用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025180502A1 (zh) * 2024-03-01 2025-09-04 上海齐鲁制药研究中心有限公司 一种联合用药物组合物及其用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2797719C (en) * 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
GB201519573D0 (en) * 2015-11-05 2015-12-23 King S College London Combination
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
US11485736B2 (en) * 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
US20230065636A1 (en) * 2020-01-15 2023-03-02 KSQ Therapeutics, Inc. Compositions of substituted pyrazolopyrimidines and uses thereof
WO2021163530A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
KR20230098186A (ko) * 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN ONCOLOGY, vol. Vol.9, Article 1406 (9 pages), JPN6025012868, 2019, ISSN: 0005563213 *
MOLECULAR CELL, vol. Vol.72, pp.925-941, JPN6025012869, 2018, ISSN: 0005563214 *

Also Published As

Publication number Publication date
IL295149A (en) 2022-09-01
KR20220140732A (ko) 2022-10-18
US20230277533A1 (en) 2023-09-07
MX2022009818A (es) 2022-09-05
EP4103165A4 (en) 2024-02-28
TW202140026A (zh) 2021-11-01
CN115066235A (zh) 2022-09-16
WO2021163530A1 (en) 2021-08-19
EP4103165A1 (en) 2022-12-21
AU2021218805A1 (en) 2022-09-01
CA3168009A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP2023514568A (ja) ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤を含む治療効果のある組み合わせ
Yuan et al. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Smith et al. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy
KR102446839B1 (ko) B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
US11986463B2 (en) Combination therapy for the treatment of gastrointestinal stromal tumor
CN106659716A (zh) 阿吡莫德组合物及其使用方法
CN114246864B (zh) Csf1r激酶抑制剂及其用途
TW202332431A (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
TW201217361A (en) Method of treating abnormal cell growth
EP3365468A1 (en) Polymerase q as a target in hr-deficient cancers
US20220047573A1 (en) Methods for treating vascular malformations
WO2022217060A1 (en) Cancer treatment using parp inhibitors and plk1 inhibitors
JP2025533524A (ja) ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤およびｐａｒｐ１特異的阻害剤を含む治療的組合せ
TWI891650B (zh) 治療血管畸形之方法
JP2020520385A (ja) 癌治療のための薬剤の組み合わせ
EA048213B1 (ru) Терапевтические комбинации, содержащие ингибиторы убиквитин-специфической протеазы 1 (usp1) и ингибиторы поли(адф-рибоза)полимеразы (parp)
KR20240055021A (ko) Tead 저해제에 대한 투여 요법
WO2024088193A1 (en) Combination of aurora a and parp inhibitors for treatment of cancers
HK40120637A (zh) 包含泛素特异性加工蛋白酶1(usp1)抑制剂和parp1-选择性抑制剂的治疗组合
TW202506115A (zh) 一種藥物組合及其應用
KR20240044419A (ko) Erk1/2 및 egfr 억제제 조합 요법
WO2026096660A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
CN120456904A (zh) 用于治疗胶质母细胞瘤的组合治疗
Nitschmann Anti-neoplastic Activity of Topoisomerase I Inhibitor Etirinotecan Pegol (NKTR-102) and PARP Inhibitor Rucaparib (CO-388) Against Ovarian Cancer Patient Derived Xenograft Models

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240606

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111